This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
shingrix-rzv
Shingrix (RZV)
Adjuvanted recombinant subunit zoster vaccine; VZV glycoprotein E antigen + AS01B adjuvant (MPL + QS-21 liposomes). Two IM doses 2–6 months apart. ZOE-50: 97% efficacy in adults ≥50; ZOE-70: 91% in ≥70. Preferred over live-attenuated Zostavax; approved for immunocompromised.
Entry Metadata
| Field | Value |
|---|---|
| ID | shingrix-rzv |
| Name | Shingrix (RZV) |
| Status | active |
| Last reviewed | 2026-06-06 |
| Platform | 03 — Recombinant Subunit |
| Delivery system | lyophilized antigen reconstituted with liquid AS01B adjuvant system (MPL + QS-21 in liposome formulation) |
| Adjuvants | AS01B (monophosphoryl lipid A [MPL] + QS-21 saponin in liposomes) |
| Route | intramuscular |
| Dose schedule | 2-dose series: dose 1 at election, dose 2 two to six months later; no booster currently recommended |
| Manufacturer | GlaxoSmithKline (GSK) |
| Cold chain | 2–8°C; do not freeze; store in original packaging to protect from light; reconstituted vaccine must be used within 6 hours |
Cross-Atlas Connections
Sources
- Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087-2096. · PubMed 25981865
- Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019-1032. · PubMed 27626517
- Dagnew AF, Ilhan O, Lee WS, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988-1000. · PubMed 31285139